Government biomarker accountability doctrine governance

Introduction

Government Biomarker Accountability Doctrine Governance refers to the legal and institutional framework through which governments are held accountable for the collection, processing, interpretation, sharing, storage, and use of biological markers derived from individuals. Biomarkers may include genetic variants, genomic information, biochemical indicators, physiological measurements, immune responses, and other biological information capable of revealing information about a person's health or biological characteristics. As governments increasingly use biomarkers in public-health surveillance, disease screening, environmental-health programmes, criminal investigations, research, and population monitoring, questions of legality, privacy, consent, discrimination, proportionality, and institutional accountability become increasingly important.

The doctrine is not generally recognised as a single, universally codified rule of international law. Rather, it can be understood as an emerging combination of constitutional privacy principles, data-protection law, medical ethics, administrative law, human-rights law, and public-sector accountability mechanisms. Its central proposition is that governmental possession or technological capacity to process biological information does not itself create unlimited legal authority to use it.

Meaning and scope of biomarker accountability

Government accountability begins with establishing a lawful purpose for biomarker collection. A public authority should be able to identify the legislation, regulation, constitutional authority, or other legal basis permitting the collection and processing of biological information. The purpose should be sufficiently specific to prevent governments from collecting extensive biological information merely because it might become useful in the future.

Biomarker governance also requires proportionality. Where the State collects particularly sensitive biological information, the government should demonstrate that the measure pursues a legitimate public objective and that the interference with individual rights is necessary and proportionate. Less intrusive alternatives should be considered before compulsory biomarker collection is authorised.

Another important element is transparency. Individuals should ordinarily understand why their biological information is being collected, who will have access to it, how long it will be retained, and for what purposes it may subsequently be used. Public authorities should maintain appropriate records and establish mechanisms for independent auditing and review.

Constitutional and human-rights foundations

The strongest legal foundation for governmental biomarker accountability comes from privacy and bodily-autonomy rights. Biological information can reveal intimate information about health, hereditary characteristics, susceptibility to disease, and familial relationships. Consequently, governmental biomarker programmes may engage constitutional protections even where the State does not physically interfere with the individual.

In Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1, the Supreme Court of India recognised privacy as a fundamental right under Article 21 and other constitutional guarantees. The Court emphasised legality, legitimate State purpose, and proportionality when assessing restrictions on privacy. These principles provide an important framework for evaluating government collection and processing of sensitive biological information.

The subsequent K.S. Puttaswamy (Aadhaar) v. Union of India, (2019) 1 SCC 1 decision is particularly relevant because Aadhaar involved biometric information and large-scale governmental databases. The Supreme Court examined questions concerning statutory authority, privacy, informational autonomy, and proportionality. Although biometric identification is not identical to biomarker governance, the reasoning demonstrates that governmental collection of biological identifiers must remain connected to a legally authorised and constitutionally legitimate purpose.

Data protection and institutional responsibility

Modern biomarker governance increasingly requires governments to treat biological information as highly sensitive personal information. Data-protection principles such as purpose limitation, data minimisation, security safeguards, retention limitation, accuracy, access controls, and accountability therefore become important.

Government agencies should establish clear institutional responsibilities. A department collecting biomarkers should not necessarily have unrestricted authority to determine secondary uses, disclosure arrangements, retention periods, and research access. Independent ethics committees, privacy officers, data-protection authorities, judicial oversight, legislative scrutiny, and audit institutions can provide additional safeguards.

The General Data Protection Regulation (GDPR) of the European Union provides an influential model. Genetic and biometric data receive heightened protection under Article 9, subject to specified exceptions. Although the GDPR is not itself a universal rule governing every government biomarker programme, its principles illustrate how sensitive biological information can be subjected to stronger legal safeguards.

Relevant case laws

S. and Marper v. United Kingdom, (2008) 48 EHRR 50 is highly significant. The European Court of Human Rights considered the indefinite retention of fingerprints, cellular samples, and DNA profiles of individuals who had not been convicted. The Court found that blanket and indiscriminate retention violated Article 8 of the European Convention on Human Rights. The case demonstrates that even information originally collected for legitimate law-enforcement purposes cannot necessarily be retained indefinitely without adequate safeguards.

In Gaughran v. United Kingdom, Application No. 45245/15 (ECtHR, 2020), the Court again considered retention of biometric and personal information by law-enforcement authorities. The judgment reinforced the importance of safeguards governing the retention and destruction of sensitive information.

In M.S. v. Sweden, (1997) 3 BHRC 248, the European Court of Human Rights recognised that medical information is closely connected with private life. Unjustified disclosure of sensitive medical information can therefore constitute serious interference with privacy.

In Carpenter v. United States, 585 U.S. 296 (2018), the United States Supreme Court recognised heightened privacy concerns concerning extensive digital records capable of revealing detailed information about an individual's movements. Although the case did not concern biomarkers directly, its reasoning supports the broader principle that technologically aggregated personal information may require stronger constitutional protection.

Accountability for government misuse

A mature biomarker accountability framework should impose responsibility not only for unlawful collection but also for misuse after collection. Government agencies may face accountability where information is disclosed without lawful authority, used for an unrelated purpose, retained unnecessarily, inadequately secured, or used to make consequential decisions without appropriate safeguards.

Particular concern arises where biomarkers are used for automated or algorithmic decision-making. For example, a government should not automatically deny benefits, healthcare access, employment opportunities, immigration status, or other legal entitlements merely because a biological indicator suggests a particular characteristic or health risk. Scientific uncertainty, false positives, population bias, and limitations of biomarker technology must be considered.

Administrative-law principles of reasonableness, fairness, natural justice, and judicial review can therefore supplement privacy protections. Affected persons should, where appropriate, have avenues to challenge governmental decisions based upon biological information.

Public-health applications

Biomarker governance becomes especially complex during public-health emergencies. Governments may have legitimate reasons to collect biological information for disease surveillance, outbreak control, vaccination programmes, or epidemiological research. Nevertheless, emergency circumstances do not automatically eliminate constitutional and human-rights obligations.

The European Court of Human Rights decision in Vavřička and Others v. Czech Republic, Applications Nos. 47621/13 and others (2021) illustrates the Court's approach to compulsory public-health measures. The Court accepted that public-health objectives can justify significant interference with individual interests where the measure has a sufficient legal basis and appropriate safeguards. The case demonstrates the importance of balancing individual autonomy against collective health interests.

Consequently, emergency biomarker programmes should incorporate sunset clauses, periodic review, narrowly defined purposes, security requirements, and deletion or anonymisation mechanisms when the emergency justification ends.

Governance principles

A comprehensive Government Biomarker Accountability Doctrine can therefore be organised around several principles:

• Legality: biomarker collection must have a clear legal foundation.
• Legitimate purpose: information should be collected for a defined public purpose.
• Necessity and proportionality: intrusive collection should be justified by demonstrable need.
• Data minimisation: governments should collect only information reasonably necessary for the stated purpose.
• Purpose limitation: information should not automatically be repurposed for unrelated governmental objectives.
• Security: strong technical and organisational safeguards should protect biological information.
• Transparency: individuals and the public should receive meaningful information about major biomarker programmes.
• Independent oversight: governmental programmes should be subject to institutional and, where appropriate, judicial review.
• Retention limitation: sensitive biological information should not be retained indefinitely without justification.
• Remedy: individuals should have mechanisms for challenging unlawful collection, disclosure, or governmental decisions.
• Non-discrimination: biomarker-based governance should not produce unjustified discriminatory outcomes.

Conclusion

Government Biomarker Accountability Doctrine Governance represents an emerging field at the intersection of privacy law, constitutional law, biotechnology regulation, public health, data protection, and administrative accountability. Its fundamental principle is that the State's ability to collect or analyse biological information must remain subject to law and institutional control.

Cases such as Puttaswamy, Puttaswamy (Aadhaar), S. and Marper, Gaughran, and Vavřička demonstrate the legal importance of proportionality, privacy, purpose limitation, retention safeguards, and legitimate public objectives. Future biomarker governance will increasingly require governments to combine scientific expertise with constitutional safeguards so that technological advances serve public interests without creating uncontrolled systems of biological surveillance.